نتائج البحث - "Ander Urruticoechea"

1

Abstract PS5-39: Tumour cellularity size as a biomarker to predict response after neoadjuvant endocrine therapy: Correlation analysis between Ki67 expression and PEPI score

المؤلفون: Ainhara Lahuerta, María Otaño, Virginia Segur, Lide Larburu, María M. Caffarel, Joanna Ines Lopez Velazco, Juan Carlos Irizabal, Kepa Elorriaga, Lourdes Jáuregui, Ana Martínez, Ander Urruticoechea

المصدر: Cancer Research. 81:PS5-39

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, Correlation analysis, medicine, Endocrine therapy, Biomarker (medicine), business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::053557de1857a24dd11199bca4127e35
https://doi.org/10.1158/1538-7445.sabcs20-ps5-39

2

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis

المؤلفون: Xavier Pivot, Ander Urruticoechea, Ian E. Krop, Noman Paracha, Adriana Reyes, Véronique Diéras

المصدر: Breast Cancer Research and Treatment

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6d734dba58a426e35a3c9ffacb1dc21
https://doi.org/10.1007/s10549-020-05577-7

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

3

Altered Levels of Desaturation and ω-6 Fatty Acids in Breast Cancer Patients' Red Blood Cell Membranes

المؤلفون: Joana Camba, Gurutze Ugartemendia, Nerea Bretaña, Carla Ferreri, Javier Amézaga, Ander Urruticoechea, Aizpea Iruretagoyena, Aitziber Larraioz, Itziar Tueros

المصدر: Metabolites
Metabolites, Vol 10, Iss 469, p 469 (2020)
Volume 10
Issue 11

مصطلحات موضوعية: 0301 basic medicine, linoleic acid, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Linoleic acid, lcsh:QR1-502, membrane lipidome, red blood cell, medicine.disease_cause, Biochemistry, lcsh:Microbiology, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, breast cancer, Internal medicine, medicine, arachidonic acid, Molecular Biology, chemistry.chemical_classification, business.industry, Cancer, Fatty acid, omega 6, medicine.disease, Red blood cell, 030104 developmental biology, Endocrinology, medicine.anatomical_structure, chemistry, 030220 oncology & carcinogenesis, Arachidonic acid, Carcinogenesis, business, SCD1, Polyunsaturated fatty acid

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::834c95d8ec9637836cab01153e30f8c7
https://pubmed.ncbi.nlm.nih.gov/33212920

Find this article in full text from ProQuest

4

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

المؤلفون: Sara Benito, Jesus Corral, Susana Bezares, Helena Colom, Eva Carrasco, Ander Urruticoechea, Miguel Martin, Jose Manuel Trigo, Yolanda Jerez, José A. García-Sáenz, Federico Rojo, Silvia Antolín, Rosalia Caballero, Begoña Jiménez, Nuria Gonzalo, Carmen Muñoz, Manuel Ruiz-Borrego

المصدر: Investigational New Drugs. 37:98-108

مصطلحات موضوعية: Adult, 0301 basic medicine, Oncology, medicine.medical_specialty, Maximum Tolerated Dose, Pyridines, Triple Negative Breast Neoplasms, Docetaxel, Neutropenia, Sonidegib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Tissue Distribution, Pharmacology (medical), Adverse effect, Triple-negative breast cancer, Aged, Pharmacology, Leukopenia, business.industry, Biphenyl Compounds, Carcinoma, Ductal, Breast, Cancer, Middle Aged, Prognosis, medicine.disease, Smoothened Receptor, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Female, medicine.symptom, Smoothened, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72733e7dd65b57bdabeb2af0cb89aee7
https://doi.org/10.1007/s10637-018-0614-9

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

5

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

المصدر: Cancer Research. 78:PD5-10

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b6d1e958cce9b58ebb9ab3905b547b39
https://doi.org/10.1158/1538-7445.sabcs17-pd5-10

6

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

المؤلفون: Patrick Urban, Barbara Pistilli, Emmanuelle di Tomaso, D. Farci, Cristian Massacesi, Ander Urruticoechea, Cristina Saura, Anthony Kong, H. S. Han, Steve Chan, Guy Jerusalem, S. L. Mouhaer, Thomas Bachelot, Douglas Robinson, T. Pluard

المصدر: Breast Cancer Res Treat

مصطلحات موضوعية: Adult, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Maximum Tolerated Dose, Receptor, ErbB-2, Morpholines, Buparlisib, Aminopyridines, Phases of clinical research, Breast Neoplasms, Article, Capecitabine, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Humans, skin and connective tissue diseases, Response Evaluation Criteria in Solid Tumors, Aged, Brain Neoplasms, business.industry, Cancer, Middle Aged, medicine.disease, Metastatic breast cancer, 030104 developmental biology, Tolerability, chemistry, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Disease Progression, Female, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0295573631a0708fca0b7ba8d906a3f5
https://doi.org/10.1007/s10549-017-4596-7

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

7

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy

المؤلفون: Ander Urruticoechea, Seock-Ah Im, Antonio Carlos Sánchez Ruiz, M. Rizwanullah, J Eng-Wong, István Láng, Montserrat Muñoz, Hannah Douthwaite, Gianluca Tomasello, Tanja Badovinac Crnjevic, Sarah Heeson

المصدر: Journal of Clinical Oncology. 35:3030-3038

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9246c788965514def420ce4e7cf5d6ed
https://doi.org/10.1200/jco.2016.70.6267

8

129TiP Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR)[+]/HER2[–] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA

المصدر: Annals of Oncology. 32:S77

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Fulvestrant, business.industry, Advanced breast, Cancer, Hematology, medicine.disease, Metformin, Hormone receptor, Internal medicine, Medicine, In patient, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::0d3ec1f7aae690d318d2909566c9a743
https://doi.org/10.1016/j.annonc.2021.03.143

9

14P Immunomodulatory effect of denosumab in early breast cancer: Preliminary results of a randomized window-opportunity clinical trial D-Biomark

المصدر: Annals of Oncology. 32:S26

مصطلحات موضوعية: Clinical trial, Oncology, medicine.medical_specialty, Denosumab, business.industry, Internal medicine, medicine, Window (computing), Hematology, business, medicine.drug, Early breast cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::abb6772d6352b07ae48a5dfba3d7b62b
https://doi.org/10.1016/j.annonc.2021.03.028

10

Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

المؤلفون: Nuria Ribelles, Sara Benito, Sonia Pernas, Ander Urruticoechea, Rosalia Caballero, Juan Carlos Montero, Silvia Antolín, Javier Orlando, Atanasio Pandiella, Eva Carrasco, Alejandro Falcon, M. J. Escudero, Alberto Ocaña, Federico Rojo, Alvaro Montaño, María Atienza, M. Gil-Martin, Manuel Ruiz-Borrego

المساهمون: Bristol Myers Squibb Foundation

المصدر: Digital.CSIC. Repositorio Institucional del CSIC
instname

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, Dasatinib, chemistry.chemical_compound, 0302 clinical medicine, Trastuzumab, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Phosphorylation, skin and connective tissue diseases, Trastuzumab resistance, Extracellular Signal-Regulated MAP Kinases, Aged, 80 and over, Middle Aged, Metastatic breast cancer, Phase II, Treatment Outcome, Paclitaxel, 030220 oncology & carcinogenesis, Female, SRC kinase inhibitor, medicine.drug, Adult, medicine.medical_specialty, Proto-Oncogene Proteins pp60(c-src), Breast Neoplasms, Neutropenia, Drug Administration Schedule, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Humans, Adverse effect, HER2-positive breast cancer, neoplasms, Aged, business.industry, medicine.disease, Survival Analysis, 030104 developmental biology, chemistry, Pharmacodynamics, business, Proto-Oncogene Proteins c-akt

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae4e5e7763a60366c781c8859eecd331
https://pubmed.ncbi.nlm.nih.gov/30607629

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

تنقيح النتائج